List of Excipients in Branded Drug GAMMAPLEX

« Back to Dashboard

GAMMAPLEX Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Gammaplex is a plasma-derived human immune globulin intravenous product manufactured by Bio Products Laboratory, now part of the Kedrion group. Its commercial formulation uses a restrained excipient system centered on glycine and polysorbate 80. The main opportunity is not broad excipient substitution. It is targeted differentiation through stability, administration convenience, supply security, low-surfactant formulations, and new presentation formats that preserve immunoglobulin quality and FDA comparability.

What excipients are used in Gammaplex?

Gammaplex 5% and Gammaplex 10% contain human immunoglobulin G, glycine, polysorbate 80, and Water for Injection. The products do not contain a preservative. The formulation is adjusted to an acidic pH range and is supplied for intravenous administration.[1]

Attribute	Gammaplex formulation
Active ingredient	Human normal immunoglobulin G
Concentrations	5% and 10%
Primary stabilizer	Glycine
Surfactant	Polysorbate 80
Diluent	Water for Injection
Preservative	None
Administration	Intravenous infusion
Product type	Plasma-derived biologic
FDA regulatory pathway	Biologics license application
Key quality risks	Aggregation, subvisible particles, oxidation, viscosity, complement activation

Glycine provides protein stabilization and supports the formulation’s osmolality and pH environment. Polysorbate 80 reduces protein adsorption at liquid-air and container interfaces and helps limit stress-induced aggregation during storage, shipping, and infusion preparation.

The excipient platform is commercially important because immunoglobulin products are sensitive to thermal stress, agitation, freeze-thaw exposure, oxidation, and interaction with processing equipment. Changes that appear minor from a small-molecule perspective can alter aggregate levels, particle formation, potency, or infusion tolerability.

How does the Gammaplex excipient system support product stability?

The Gammaplex formulation uses a conventional protein-stabilization approach with a limited number of excipients. This reduces formulation complexity but places greater importance on manufacturing controls and raw-material quality.

Glycine as the principal stabilizer

Glycine can stabilize immunoglobulin structure by modifying the solution environment and reducing the tendency of proteins to unfold or associate under storage stress. It also supports an acceptable osmolality profile for intravenous administration.

Commercial advantages include:

• Established regulatory history in immunoglobulin products.
• Broad availability from qualified pharmaceutical suppliers.
• Low formulation complexity.
• Compatibility with liquid, ready-to-use presentations.
• A relatively clear excipient safety profile at established concentrations.

The principal limitation is that glycine does not eliminate all degradation pathways. It does not independently control surfactant oxidation, protein oxidation, particulate formation, or container-surface interactions.

Polysorbate 80 as an interfacial protectant

Polysorbate 80 protects immunoglobulin against adsorption and aggregation at air-liquid, glass-liquid, and polymer-liquid interfaces. It is widely used in biologics, vaccines, and protein therapeutics.

Its main technical liabilities are:

• Hydrolysis during long-term storage.
• Formation of free fatty acids.
• Oxidation of unsaturated fatty-acid components.
• Potential generation of particles.
• Lot-to-lot variability in impurity profile.
• Interaction with trace metals and oxygen exposure.

For Gammaplex, polysorbate control is a quality-by-design issue. A commercial excipient strategy should monitor peroxide value, acid value, moisture, residual solvents, trace metals, and degradation products. Supplier qualification should include manufacturing-site controls and change-notification obligations.

What formulation patents protect Gammaplex?

Gammaplex is a biologic product rather than a conventional small-molecule drug. Its commercial protection may involve a combination of biologics patent claims, manufacturing know-how, plasma-pool controls, viral-clearance processes, formulation parameters, container systems, and regulatory exclusivity.

The FDA Orange Book generally does not provide the primary patent framework for biologics such as Gammaplex. Orange Book patent listings principally cover approved small-molecule drug products. Biologic patent and exclusivity analysis instead requires review of the BLA, FDA regulatory records, public patent databases, and litigation filings.[2]

No defensible commercial conclusion should assume that the presence of glycine and polysorbate 80 alone creates a meaningful blocking patent position. Those excipients are widely used. Stronger protection would normally arise from narrower combinations, such as:

• Defined immunoglobulin concentration and pH ranges.
• Specific polysorbate concentration windows.
• Limits on aggregates or particles after accelerated storage.
• Low-temperature or agitation-resistant formulations.
• Container-closure systems that reduce adsorption.
• Manufacturing steps that preserve subclass distribution.
• Viral-inactivation and filtration sequences.
• Plasma-pool and purification controls linked to product quality.
• Lyophilized or alternative presentations with improved stability.

Can an excipient change create freedom-to-operate risk?

Yes. A competing product can avoid a formulation claim but still infringe manufacturing, container, process, or method-of-use claims. The relevant analysis should compare:

1. Excipient identity and concentration.
2. pH and osmolality.
3. Protein concentration.
4. Aggregate and particle specifications.
5. Processing sequence.
6. Viral-clearance process.
7. Container and administration system.
8. Labelled indications and dosing instructions.

A substitution from polysorbate 80 to polysorbate 20, poloxamer, or another surfactant is not automatically non-infringing. It also may trigger a comparability burden and new stability work.

What excipient alternatives could improve Gammaplex?

The most credible alternatives fall into four categories: surfactant replacement, antioxidant control, buffer modification, and presentation redesign.

Polysorbate 20

Polysorbate 20 is the closest practical alternative to polysorbate 80. It can reduce certain oxidation and hydrolysis concerns, but it is not universally superior. Performance depends on immunoglobulin composition, concentration, pH, container material, oxygen exposure, and sterilizing filtration.

Potential commercial benefit:

• A differentiated low-polysorbate or polysorbate-20 formulation.
• A patentable formulation window if supported by unexpected stability results.
• Reduced risk from specific polysorbate 80 degradation pathways.

Key development burden:

• Head-to-head aggregation studies.
• Oxidation and particle testing.
• Compatibility with manufacturing equipment.
• Long-term and accelerated stability.
• Infusion tolerability assessment.
• Comparability to the marketed product.

Poloxamers

Poloxamer 188 and related nonionic surfactants can reduce interfacial stress and may provide an alternative to polysorbates. Their use in an immunoglobulin product would require careful control of viscosity, micelle behavior, extractables, filtration performance, and compatibility with the plasma-derived protein mixture.

Commercial opportunity is strongest where a poloxamer system demonstrates:

• Lower particle formation.
• Better agitation resistance.
• Improved shipping stability.
• Lower oxidation burden.
• Comparable infusion tolerability.

The risk is that a novel surfactant system may require extensive clinical and regulatory justification because the product is a complex mixture of immunoglobulin molecules rather than a single recombinant protein.

Histidine or citrate buffer systems

Histidine and citrate can provide alternative buffering environments. They may support a different pH profile or improve stability under selected stress conditions. Their use must be evaluated against:

• Immunoglobulin aggregation.
• Complement activation.
• Pain or tolerability during infusion.
• Osmolality.
• Interaction with trace metals.
• Container compatibility.

A buffer change is less commercially attractive if it does not produce a measurable improvement in shelf life, infusion rate, cold-chain resilience, or patient experience.

Antioxidant systems

Methionine, chelators, or oxygen-control strategies may reduce oxidation. These approaches require particular caution in plasma-derived products. The objective is to limit degradation without introducing a new impurity profile or altering immunoglobulin function.

Commercially, oxygen-management may be more practical than adding a new antioxidant. Options include:

• Low-oxygen headspace.
• Nitrogen sparging.
• Improved stopper and bag-barrier performance.
• Lower peroxide excipient specifications.
• Light-protective packaging.
• Metal-ion control.

These measures may be protectable through process or packaging claims even where the excipient composition remains unchanged.

What commercial opportunities exist for Gammaplex excipients?

The strongest opportunities are adjacent to the existing formulation rather than a complete reformulation.

Opportunity	Commercial value	Technical difficulty	Regulatory burden
Low-peroxide polysorbate 80 sourcing	Medium	Low	Low to medium
Polysorbate 20 reformulation	Medium to high	Medium	Medium to high
Poloxamer-based formulation	High if successful	High	High
Oxygen-controlled packaging	Medium	Medium	Medium
Longer room-temperature stability	High	High	High
Reduced infusion time	High	High	High
Ready-to-use smaller-volume bags	Medium	Medium	Medium
Pediatric or weight-based presentations	Medium	Medium	Medium
Subcutaneous immune globulin conversion	Very high	Very high	Very high
Excipient supplier licensing	Medium	Low to medium	Low

Longer room-temperature stability

Immune globulin products generally depend on controlled storage and careful handling. A formulation or package that tolerates longer room-temperature excursions could reduce logistics costs and improve use in outpatient, home-care, military, and emergency settings.

The commercial value depends on demonstrated stability under:

• Repeated temperature excursions.
• Agitation during transport.
• Light exposure.
• Freeze-thaw events.
• Extended hold times after vial or bag entry.

A validated room-temperature window could support premium pricing, hospital formulary preference, and reduced product wastage.

Shorter infusion time

Infusion duration affects clinic capacity and total treatment cost. Excipients alone will not determine infusion speed. The product must also maintain acceptable viscosity, tolerability, renal-risk controls, and aggregate specifications at higher administration rates.

A differentiated formulation that permits faster infusion could compete on total cost of care rather than acquisition price. This is particularly relevant for chronic inflammatory demyelinating polyneuropathy, primary immunodeficiency, and immune thrombocytopenia treatment settings.

Ready-to-use and smaller-volume presentations

Gammaplex 10% already reduces infusion volume relative to a 5% solution. Further commercial opportunities include:

• Small-volume vials for dose rounding.
• Larger-volume bags for high-dose adult treatment.
• Pediatric presentations that reduce wastage.
• Pharmacy-friendly carton configurations.
• Closed-system administration compatibility.
• Reduced overfill and improved extractable volume.

These changes may not require a new active ingredient, but they can improve purchasing efficiency and reduce nursing time.

What is the FDA regulatory status of Gammaplex?

Gammaplex is licensed in the United States under a biologics license application. FDA-approved indications include primary immunodeficiency, chronic immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy, subject to the specific labeling for the approved concentration and presentation.[1]

A material excipient change would generally require a supplement to the BLA. The regulatory pathway depends on the extent of the change and its effect on product quality.

Likely regulatory categories

Minor changes may involve:

• Tightening excipient specifications.
• Changing an approved supplier under comparability protocols.
• Adjusting container components with demonstrated equivalence.
• Modifying oxygen-control procedures.

More significant changes may involve:

• Replacing polysorbate 80.
• Changing buffer composition.
• Altering protein concentration.
• Moving from vial to bag or another delivery system.
• Claiming a new infusion rate or stability period.
• Introducing a new route of administration.

FDA review will focus on product comparability, aggregate profile, potency, purity, identity, safety, stability, and clinical relevance. Plasma-derived products also require continuing control of donor screening, plasma-pool testing, viral clearance, and manufacturing consistency.[3]

When does Gammaplex lose exclusivity?

Gammaplex does not have a simple small-molecule patent-expiration answer. The product’s competitive exposure depends on BLA exclusivity, patent rights, manufacturing capability, regulatory requirements, and the availability of a legally permitted follow-on pathway.

Biologics receive statutory reference-product exclusivity under the Public Health Service Act. The period is generally 12 years from first licensure for eligible reference products, although the practical impact depends on the product’s approval history and whether a follow-on applicant can rely on the reference product’s data.[4]

For Gammaplex, relevant competitive barriers include:

• Reference-product exclusivity.
• Product-specific formulation and process patents.
• Manufacturing know-how.
• Plasma sourcing.
• Viral-clearance validation.
• Facility capacity.
• FDA inspection history.
• Hospital contracting.
• Supply reliability.

A competitor may face a more significant manufacturing barrier than an excipient barrier. Human immunoglobulin is a complex plasma-derived product, and consistent production requires qualified plasma, validated fractionation, purification, viral reduction, and release testing.

Are Paragraph IV challenges or biosimilar risks relevant to Gammaplex?

Paragraph IV litigation is principally associated with abbreviated new drug applications for small-molecule products under the Hatch-Waxman Act. It is not the standard pathway for a plasma-derived biologic such as Gammaplex.

The relevant follow-on risk is a competing biologic or biological product application, subject to the statutory and regulatory framework applicable to biologics. A follow-on applicant would need to address product quality, clinical performance, immunogenicity, manufacturing comparability, and the complexity of the immunoglobulin mixture.

Biosimilar risk is therefore different from generic risk:

Risk factor	Conventional generic	Gammaplex follow-on
Active ingredient	Chemically defined molecule	Complex human immunoglobulin mixture
Main approval route	ANDA	Biologics pathway or separate BLA
Formulation copying	Usually straightforward	Does not establish full product equivalence
Manufacturing barrier	Moderate	High
Plasma sourcing	Not relevant	Critical
Immunogenicity assessment	Limited	Important
Substitution	Governed by generic rules	Interchangeability depends on biologic standards
Price erosion	Often rapid	More gradual and supply dependent

Which companies compete with Gammaplex?

Gammaplex competes in the intravenous immune globulin market with products such as Privigen, Gamunex-C, Octagam, Panzyga, Flebogamma DIF, and other licensed human immune globulin products. Major manufacturers include CSL Behring, Grifols, Octapharma, Takeda, Kedrion, and other plasma-product companies.

Competition is based on more than excipients. Buyers evaluate:

• Indication coverage.
• Dose flexibility.
• Infusion rate.
• Adverse-event profile.
• Sodium and sugar content.
• Storage requirements.
• Supply continuity.
• Contract price.
• Hospital and specialty-pharmacy service.
• Patient access and reimbursement.

Gammaplex’s excipient system is therefore most commercially useful when linked to a measurable product attribute, such as lower particle burden, improved temperature excursion tolerance, reduced infusion reactions, or faster administration.

What patent litigation and settlement issues affect Gammaplex?

The principal legal risks are likely to arise from process, formulation, manufacturing, and biologics competition rather than conventional Paragraph IV litigation. A serious freedom-to-operate review should search claims covering:

• Immunoglobulin purification.
• Protein stabilization.
• Polysorbate or alternative surfactant systems.
• Viral inactivation.
• Nanofiltration.
• Low-temperature fractionation.
• Container-closure systems.
• Immunoglobulin formulations for CIDP, ITP, or primary immunodeficiency.
• Dose and infusion protocols.

Settlement agreements would matter if they establish a date for a competing biologic or create restrictions on manufacturing, supply, or launch. Publicly available litigation records should be reviewed before assigning a launch probability or estimating revenue erosion.

How strong is the Gammaplex excipient strategy?

The existing strategy is operationally strong but offers limited standalone differentiation. Glycine and polysorbate 80 are familiar, scalable excipients with established regulatory precedent. That lowers development risk and supports reliable manufacture.

Its weaknesses are exposure to:

• Polysorbate degradation.
• Surfactant raw-material variability.
• Protein aggregation under stress.
• Limited formulation exclusivity.
• Competition from other 5% and 10% immune globulin products.
• Dependence on plasma supply and specialized manufacturing.

The highest-value strategy is a layered protection model:

1. Retain the established formulation for supply continuity.
2. Tighten excipient and oxidation specifications.
3. Develop a second formulation with a differentiated surfactant or oxygen-control system.
4. Protect the formulation, process, package, and stability profile with separate patent families.
5. Link the technical improvement to a commercial claim, such as faster infusion or longer excursion stability.
6. Build supplier redundancy for glycine, polysorbate 80, packaging components, and critical filtration materials.

Key Takeaways

• Gammaplex uses a simple excipient system based on glycine, polysorbate 80, and Water for Injection.
• The principal technical risks are aggregation, polysorbate degradation, oxidation, particles, and container interaction.
• Excipient substitution is commercially attractive only when it produces a measurable improvement in stability, infusion performance, logistics, or patient handling.
• Polysorbate 20, poloxamers, oxygen-control packaging, and tighter excipient specifications are the most relevant development paths.
• Gammaplex is a biologic, so Orange Book and Paragraph IV analysis is less relevant than BLA exclusivity, biologics competition, patents, and manufacturing barriers.
• Manufacturing and plasma-supply constraints may create stronger competitive protection than the current excipient composition.
• The best commercial strategy is a layered formulation, process, packaging, and supply-chain program.

FAQs About Gammaplex Excipient and Commercial Strategy

Does Gammaplex contain polysorbate 80?

Yes. Gammaplex labeling identifies polysorbate 80 as an excipient, together with glycine and Water for Injection.[1]

Is Gammaplex preservative-free?

Yes. The marketed intravenous immune globulin formulation does not use a preservative.

Could Gammaplex be reformulated with polysorbate 20?

Potentially, but the change would require formulation, stability, comparability, manufacturing, and regulatory assessment. Polysorbate 20 is not automatically equivalent to polysorbate 80 for a plasma-derived immunoglobulin product.

Would an excipient patent block a Gammaplex competitor?

Only if the competitor practices the claimed formulation, process, or package limitations. Common excipients such as glycine and polysorbate 80 generally provide limited standalone patent exclusivity.

What is the most valuable commercial formulation improvement for Gammaplex?

A formulation that supports faster infusion or longer temperature-excursion stability would likely have the clearest economic value because it could reduce clinic capacity requirements, logistics costs, and product wastage.

References

1. U.S. Food and Drug Administration. (n.d.). Gammaplex prescribing information. Bio Products Laboratory, Ltd.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2016). Guidance for industry: Changes to an approved application for biological products.
4. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §§ 7001-7003.